JP2017527304A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527304A5
JP2017527304A5 JP2017523184A JP2017523184A JP2017527304A5 JP 2017527304 A5 JP2017527304 A5 JP 2017527304A5 JP 2017523184 A JP2017523184 A JP 2017523184A JP 2017523184 A JP2017523184 A JP 2017523184A JP 2017527304 A5 JP2017527304 A5 JP 2017527304A5
Authority
JP
Japan
Prior art keywords
genes
subject
lung cancer
identified
clusters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523184A
Other languages
English (en)
Japanese (ja)
Other versions
JP6775499B2 (ja
JP2017527304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040437 external-priority patent/WO2016011068A1/en
Publication of JP2017527304A publication Critical patent/JP2017527304A/ja
Publication of JP2017527304A5 publication Critical patent/JP2017527304A5/ja
Application granted granted Critical
Publication of JP6775499B2 publication Critical patent/JP6775499B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523184A 2014-07-14 2015-07-14 肺がん状態の評価方法 Active JP6775499B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024456P 2014-07-14 2014-07-14
US62/024,456 2014-07-14
US201562160403P 2015-05-12 2015-05-12
US62/160,403 2015-05-12
PCT/US2015/040437 WO2016011068A1 (en) 2014-07-14 2015-07-14 Methods for evaluating lung cancer status

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020126239A Division JP2020182489A (ja) 2014-07-14 2020-07-27 肺がん状態の評価方法

Publications (3)

Publication Number Publication Date
JP2017527304A JP2017527304A (ja) 2017-09-21
JP2017527304A5 true JP2017527304A5 (enExample) 2018-08-30
JP6775499B2 JP6775499B2 (ja) 2020-10-28

Family

ID=55078998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523184A Active JP6775499B2 (ja) 2014-07-14 2015-07-14 肺がん状態の評価方法
JP2020126239A Pending JP2020182489A (ja) 2014-07-14 2020-07-27 肺がん状態の評価方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020126239A Pending JP2020182489A (ja) 2014-07-14 2020-07-27 肺がん状態の評価方法

Country Status (8)

Country Link
US (2) US20160130656A1 (enExample)
EP (2) EP3916110A1 (enExample)
JP (2) JP6775499B2 (enExample)
KR (1) KR102461014B1 (enExample)
CN (2) CN114807368A (enExample)
AU (2) AU2015289758B2 (enExample)
CA (1) CA2954169A1 (enExample)
WO (1) WO2016011068A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874962A2 (en) 2005-04-14 2008-01-09 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
EP2605018A1 (en) 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CN109715830A (zh) * 2016-06-21 2019-05-03 威斯塔解剖学和生物学研究所 用于使用基因表达谱诊断肺癌的组合物和方法
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
KR102421109B1 (ko) * 2016-09-14 2022-07-14 필립모리스 프로덕츠 에스.에이. 개인의 생물학적 상태를 예측하기 위한 시스템, 방법 및 유전자 시그니처
US11244764B2 (en) 2016-12-21 2022-02-08 Cerner Innovation, Inc. Monitoring predictive models
WO2018216009A1 (en) * 2017-05-22 2018-11-29 The National Institute For Biotechnology In The Negev Ltd. Ben-Gurion University Of The Negev Biomarkers for diagnosis of lung cancer
CN110958853B (zh) * 2017-06-02 2023-08-25 威拉赛特公司 用于鉴定或监测肺病的方法和系统
WO2019126343A1 (en) 2017-12-19 2019-06-27 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
CN112399819B (zh) 2018-07-02 2024-08-23 3M创新有限公司 用于监测时间相关过程的传感系统和方法
KR102274564B1 (ko) * 2018-07-03 2021-07-07 (주) 프로큐라티오 빅데이터분석기반 암진단장치
CN108998531B (zh) * 2018-08-31 2021-10-01 昆明医科大学第一附属医院 肺癌下调长链非编码rna标志物及其应用
CN109615075B (zh) * 2018-12-14 2022-08-19 大连海事大学 一种基于多层聚类模型的居民日常行为识别方法
US20210287795A1 (en) * 2020-03-12 2021-09-16 Optellum Limited Cad device and method for assisting an estimation of lung disease from medical images
CN114277138B (zh) * 2020-03-30 2022-06-24 中国医学科学院肿瘤医院 外泌体arpc5、mboat2等在肺癌诊断中的应用
CN114410794B (zh) * 2020-03-30 2023-06-23 中国医学科学院肿瘤医院 外泌体miR-106b-3P、ARPC5在肺癌诊断中的应用
CN111863130A (zh) * 2020-04-07 2020-10-30 至本医疗科技(上海)有限公司 肿瘤免疫治疗预后标志物的筛选方法及应用
CN112034185A (zh) * 2020-09-11 2020-12-04 上海市胸科医院 Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途
IL306044A (en) * 2021-03-29 2023-11-01 Veracyte Inc Methods and systems for identifying health disorders
US12094107B2 (en) * 2021-04-07 2024-09-17 Optellum Limited CAD device and method for analyzing medical images
CN113444796B (zh) * 2021-06-29 2023-02-07 浙江医院 与肺癌相关的生物标志物及其在诊断癌症中的应用
KR102417602B1 (ko) * 2021-11-30 2022-07-07 (주)플라스바이오 인공 지능 모델 기반 종양 관리 장치 및 방법
CN114854755B (zh) * 2022-05-30 2023-05-23 陕西师范大学 一种抑制vstm2l表达的慢病毒载体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234623A1 (en) 2002-05-16 2003-12-02 Euro-Celtique, S.A. Use of gastrin releasing peptide (grp) and its receptor in cancer screening
WO2005000098A2 (en) 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
WO2005047451A2 (en) 2003-11-12 2005-05-26 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
EP1874962A2 (en) * 2005-04-14 2008-01-09 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP2605018A1 (en) 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2007142936A2 (en) * 2006-05-30 2007-12-13 Duke University Prediction of lung cancer tumor recurrence
KR101443214B1 (ko) * 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
WO2009121070A1 (en) 2008-03-28 2009-10-01 The Trustees Of Boston University Multifactorial methods for detecting lung disorders
GB0811413D0 (en) * 2008-06-20 2008-07-30 Kanton Basel Stadt Gene expression signatures for lung cancers
MX355020B (es) * 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
KR20130017525A (ko) 2011-08-11 2013-02-20 주식회사 젠닥스 대장암, 유방암, 신장암 또는 갑상선암의 조기 진단을 위한 바이오 마커 및 이의 용도
EA201490533A1 (ru) * 2011-08-29 2014-08-29 Кардиодиикс, Инк. Способы и композиции для определения статуса в отношении курения
US9753043B2 (en) * 2011-12-18 2017-09-05 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
WO2013163568A2 (en) * 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers

Similar Documents

Publication Publication Date Title
JP2017527304A5 (enExample)
US20250297325A1 (en) Source of origin deconvolution based on methylation fragments in cell-free dna samples
US12462896B2 (en) Method and system for predicting response to immune anticancer drugs
JP2014521926A5 (enExample)
JP2016517291A5 (enExample)
WO2019153595A1 (zh) 慢阻肺发病风险预测方法、服务器及计算机可读存储介质
US20200239964A1 (en) Anomalous fragment detection and classification
JP2014516413A5 (enExample)
JP2009516501A5 (enExample)
JP2013520960A5 (enExample)
EP4105943A1 (en) Method and system for predicting reaction to immuno-oncology agent
JP2016515390A5 (enExample)
JP2013058095A5 (enExample)
CN116959719A (zh) 一种数据处理方法及非小细胞肺癌脑转移风险预测系统
JP2014501496A5 (enExample)
JP2019532410A5 (enExample)
Farhadian et al. Supervised wavelet method to predict patient survival from gene expression data
US20250391500A1 (en) Method and system for predicting response to immune anticancer drugs
Singer et al. Comment on Adamzik et al.: An increased alveolar CD4+ CD25+ Foxp3+ T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality
Wirtz et al. Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF
Migała-Warchoł et al. Classification of the European Union countries with an application of the modified Human Development Index
Purwaningsih et al. A Spatial Analysis Approach for Johor’s Demographic Profile: Soft Warning of the Decline Birth Number Associated with Gender Gap in Johor
Saleeb et al. Papillary renal cell carcinoma histological, immunophenotypical and molecular characterization; new classification system with associated clinical implications.
WO2017121053A1 (zh) 一种评估目标之间冲突程度的方法及其系统
Roadknight et al. Ensemble learning of colorectal cancer survival rates